FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Aino Rajamäki; Hanne Kuitunen; Marc Sorigue; Salla Maarit Kokkonen; Outi Kuittinen; Kaisa Sunela

doi:10.1002/cam4.4924

FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Aino Rajamäki^*
, Hanne Kuitunen
, Marc Sorigue
, Salla Maarit Kokkonen
, Outi Kuittinen
, Kaisa Sunela

^*Tämän työn vastaava kirjoittaja

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

11 Sitaatiot (Scopus)

22 Lataukset (Pure)

Abstrakti

Aim: The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in case of high maximal SUV values, in detecting clinically unsuspected histologic transformations (HT) of follicular lymphoma (FL). Methods: This retrospective study included all the patients who had undergone FDG-PET/CT during primary diagnosis or relapse of FL between 2010 and 2020 at Oulu University Hospital. Results: The diagnosis changed from an indolent disease to a transformed lymphoma in >10% (7/63) of the patients who underwent diagnostic FDG-PET/CT. The HT risk associated with high SUVmax (>10) was 24% (7 of 29 performed biopsies). Four out of these seven patients with verified HT had no previous clinical suspicion of transformation. Conclusion: Our results suggest that a rebiopsy based on a high SUVmax in diagnostic FDG-PET/CT is valuable in detecting clinically unsuspected HT of FL.

Alkuperäiskieli	Englanti
Sivut	407-411
Sivumäärä	5
Julkaisu	Cancer Medicine
Vuosikerta	12
Numero	1
Varhainen verkossa julkaisun päivämäärä	2022
DOI - pysyväislinkit	https://doi.org/10.1002/cam4.4924
Tila	Julkaistu - 2023
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Rahoitus

This work was funded by the Finnish Blood Disease Research Foundation and Northern‐Savonia Cancer Society (A.R.). Other authors disclose no special funding for this research.

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

SDG 3 – Hyvä terveys ja hyvinvointi

Julkaisufoorumi-taso

Jufo-taso 1

!!ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Pääsy asiakirjaan

10.1002/cam4.4924Lisenssi: CC BY

Cancer Medicine - 2022 - Rajam ki - FDGPET CTguided rebiopsy may find clinically unsuspicious transformation ofFinal published version, 405 KBLisenssi: CC BY

https://urn.fi/URN:NBN:fi:tuni-202208206575Lisenssi: CC BY

Siteeraa tätä

@article{c23898d3cacd4022b9dcefa60a418275,

title = "FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma",

abstract = "Aim: The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in case of high maximal SUV values, in detecting clinically unsuspected histologic transformations (HT) of follicular lymphoma (FL). Methods: This retrospective study included all the patients who had undergone FDG-PET/CT during primary diagnosis or relapse of FL between 2010 and 2020 at Oulu University Hospital. Results: The diagnosis changed from an indolent disease to a transformed lymphoma in >10\% (7/63) of the patients who underwent diagnostic FDG-PET/CT. The HT risk associated with high SUVmax (>10) was 24\% (7 of 29 performed biopsies). Four out of these seven patients with verified HT had no previous clinical suspicion of transformation. Conclusion: Our results suggest that a rebiopsy based on a high SUVmax in diagnostic FDG-PET/CT is valuable in detecting clinically unsuspected HT of FL.",

keywords = "FDG-PET/CT, follicular lymphoma, histologic transformation, indolent lymphoma, SUVmax",

author = "Aino Rajam{\"a}ki and Hanne Kuitunen and Marc Sorigue and Kokkonen, \{Salla Maarit\} and Outi Kuittinen and Kaisa Sunela",

note = "Funding Information: This work was funded by the Finnish Blood Disease Research Foundation and Northern‐Savonia Cancer Society (A.R.). Other authors disclose no special funding for this research. Publisher Copyright: {\textcopyright} 2022 The Authors. Cancer Medicine published by John Wiley \& Sons Ltd.",

year = "2023",

doi = "10.1002/cam4.4924",

language = "English",

volume = "12",

pages = "407--411",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley \& Sons",

number = "1",

}

TY - JOUR

T1 - FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

AU - Rajamäki, Aino

AU - Kuitunen, Hanne

AU - Sorigue, Marc

AU - Kokkonen, Salla Maarit

AU - Kuittinen, Outi

AU - Sunela, Kaisa

N1 - Funding Information: This work was funded by the Finnish Blood Disease Research Foundation and Northern‐Savonia Cancer Society (A.R.). Other authors disclose no special funding for this research. Publisher Copyright: © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2023

Y1 - 2023

N2 - Aim: The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in case of high maximal SUV values, in detecting clinically unsuspected histologic transformations (HT) of follicular lymphoma (FL). Methods: This retrospective study included all the patients who had undergone FDG-PET/CT during primary diagnosis or relapse of FL between 2010 and 2020 at Oulu University Hospital. Results: The diagnosis changed from an indolent disease to a transformed lymphoma in >10% (7/63) of the patients who underwent diagnostic FDG-PET/CT. The HT risk associated with high SUVmax (>10) was 24% (7 of 29 performed biopsies). Four out of these seven patients with verified HT had no previous clinical suspicion of transformation. Conclusion: Our results suggest that a rebiopsy based on a high SUVmax in diagnostic FDG-PET/CT is valuable in detecting clinically unsuspected HT of FL.

AB - Aim: The purpose of the study was to evaluate the clinical impact of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) followed by a new biopsy from the site with maximum standardized uptake value (SUVmax) in case of high maximal SUV values, in detecting clinically unsuspected histologic transformations (HT) of follicular lymphoma (FL). Methods: This retrospective study included all the patients who had undergone FDG-PET/CT during primary diagnosis or relapse of FL between 2010 and 2020 at Oulu University Hospital. Results: The diagnosis changed from an indolent disease to a transformed lymphoma in >10% (7/63) of the patients who underwent diagnostic FDG-PET/CT. The HT risk associated with high SUVmax (>10) was 24% (7 of 29 performed biopsies). Four out of these seven patients with verified HT had no previous clinical suspicion of transformation. Conclusion: Our results suggest that a rebiopsy based on a high SUVmax in diagnostic FDG-PET/CT is valuable in detecting clinically unsuspected HT of FL.

KW - FDG-PET/CT

KW - follicular lymphoma

KW - histologic transformation

KW - indolent lymphoma

KW - SUVmax

U2 - 10.1002/cam4.4924

DO - 10.1002/cam4.4924

M3 - Article

AN - SCOPUS:85131631481

SN - 2045-7634

VL - 12

SP - 407

EP - 411

JO - Cancer Medicine

JF - Cancer Medicine

IS - 1

ER -

FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma

Abstrakti

Rahoitus

YK:n kestävän kehityksen tavoitteet

Julkaisufoorumi-taso

!!ASJC Scopus subject areas

Pääsy asiakirjaan

Sormenjälki

Siteeraa tätä